Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Healthcare Biotechnology
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley's 2022 Virtual Oncology Conference

Business Wire January 20, 2022

Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2022

Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance

Business Wire January 5, 2022

Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index

Business Wire December 14, 2021

Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat

Business Wire December 13, 2021

Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Business Wire December 10, 2021

 Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium

Business Wire December 6, 2021

Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Business Wire November 22, 2021

Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

Business Wire November 2, 2021

Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast

Business Wire October 26, 2021

Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit

Business Wire September 13, 2021

Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of Directors

Business Wire September 7, 2021

Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

Business Wire September 2, 2021

Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 3, 2021

Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)

Business Wire July 27, 2021

Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update

Business Wire July 27, 2021

Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

Business Wire July 20, 2021

Infinity to Present at The Keystone Symposia Precision Oncology Meeting

Business Wire June 14, 2021

Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update

Business Wire May 13, 2021

Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

Business Wire May 6, 2021